VEGFA and neoplasm: Furthermore, TKIs block receptors of the vascular endothelial growth factor (VEGF), fibroblast growth factor receptors and platelet-derived growth factor and thus inhibit tumor angiogenesis and lymphangiogenesis and cause hypoxia in malignant tissue [68].